Bristol-Myers Squibb Company (BMY) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.46, which comfortably ...

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug development. Due to developments in ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

Merck (MRK) announced a bold cost-cutting strategy aiming to save $3 billion annually by 2027, reflecting a major operational ...

When Tidmarsh was appointed to CDER, the FDA emphasised his academic and clinical credentials – including his role as ...

Johnson & Johnson (JNJ) just got a fresh "Moderate Buy" consensus from the experts, and isn’t that a sweet melody to investor ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...